Olympus Corp. (JP:7733)
:7733
Earnings Data
Report Date
Aug 12, 2026TBA (Confirmed)
Period Ending
2027 (Q1)Consensus EPS Forecast
―Last Year’s EPS
7.97Same Quarter Last Year
Based on 0 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Negative
The call presented a mix of significant near-term challenges—most notably product ship holds, FDA observations, one-off costs that reduced gross margin and a 2% revenue guidance downgrade—balanced against clear remediation plans, leadership actions, a majority of held products already released (70%), an asserted China recovery (≈5–6%), maintained midterm targets and a commitment to >100 bps margin expansion beginning FY2027. Near-term financial impact is material, but management articulated specific corrective actions and kept long-term targets unchanged.Company Guidance
Midterm Targets and Margin Commitment Maintained
Management reaffirmed the midterm 3/4/5 plan targets: mid-single-digit revenue growth and a 20%+ operating margin long-term goal, and committed to delivering more than 100 basis points of margin expansion beginning in FY2027.
China Showing Early Recovery
After several quarters of double-digit decline, China reversed trend with reported growth of approximately 5–6% in the quarter following go-to-market changes (local manufacturing, training, dedicated resources) and a new China President starting in March.
Majority of Ship-Hold Products Returned to Market
About 70% of products placed on ship hold have been released back to markets after risk reviews, reducing immediate disruption and allowing phased revenue recovery as remaining products are remediated.
Clear Remediation Plan and QA/Regulatory Actions
Company initiated a risk-based product review, global harmonization of quality systems, targeted strengthening of quality and regulatory capabilities, and active dialogue with the FDA to address observations across inspected sites.
Operational and Leadership Changes
Announced leadership appointments for global operations and technology (e.g., David Shan, Syed), and reiterated intention to develop Japanese talent; emphasized digital and operational improvements as levers for sustained cost reduction.
Cost Optimization Program Proceeding
Confirmed headcount optimization of ~2,000 positions with restructuring provision increased to JPY 31 billion (accounting/provisioning timing), with the total anticipated cost across the program unchanged and savings outlook (JPY 24 billion reduction effect) preserved.
JP:7733 Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
JP:7733 Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Feb 13, 2026 | ¥1954.50 | ¥1852.50 | -5.22% |
Nov 07, 2025 | ¥1839.50 | ¥1871.50 | +1.74% |
Aug 08, 2025 | ¥1791.50 | ¥1824.50 | +1.84% |
May 13, 2025 | ¥2021.00 | ¥2017.00 | -0.20% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Olympus Corp. (JP:7733) report earnings?
Olympus Corp. (JP:7733) is schdueled to report earning on Aug 12, 2026, TBA (Confirmed).
What is Olympus Corp. (JP:7733) earnings time?
Olympus Corp. (JP:7733) earnings time is at Aug 12, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Olympus Corp. stock?
The P/E ratio of Olympus is N/A.
What is JP:7733 EPS forecast?
Currently, no data Available